Highlights
- EPS (TTM)
- -$16.05
- Gross Profit (TTM)
- -$1.11K
- EBITDA (TTM)
- -$5.04M
- Year Range
- $5.94 - $16.92
- ROA (TTM)
- -45.26%
- ROE (TTM)
- -84.99%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Decoy Therapeutics Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Decoy Therapeutics Inc
- 1D
- -3.39%
- 1M
- -20.09%
- YTD
- —
- 6M
- —
- 1Y
- —
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Jan 7, 2026, DCOY's average daily return is -0.27%, while the average monthly return is -13.32%.
Historically, 0% of months were positive and 100% were negative. The best month was Jan 2026 with a return of -8.2%, while the worst month was Mar 2026 at -20.1%. The longest winning streak lasted 0 consecutive months, and the longest losing streak was 3 months.
On a daily basis, DCOY closed higher 40% of trading days. The best single day was Jan 13, 2026 with a return of +53.4%, while the worst single day was Jan 14, 2026 at -30.4%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -8.23% | -11.66% | -20.09% | -35.21% |
Return for Risk
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Decoy Therapeutics Inc (DCOY) and compare them to a chosen benchmark (S&P 500 Index).
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Decoy Therapeutics Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Decoy Therapeutics Inc was 58.00%, occurring on Mar 27, 2026. The portfolio has not yet recovered.
The current Decoy Therapeutics Inc drawdown is 56.46%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -58% | Jan 14, 2026 | 51 | Mar 27, 2026 | — | — | — |
| -8.33% | Jan 8, 2026 | 1 | Jan 8, 2026 | 3 | Jan 13, 2026 | 4 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Decoy Therapeutics Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Decoy Therapeutics Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |